Israel Englander Department of Ophthalmology

A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according to a study led by Weill Cornell Medicine researchers.

A historic investment from Board of Fellows member Israel Englander will advance Weill Cornell Medicine’s growing research enterprise and support critical initiatives throughout the institution. 

Researchers at Weill Cornell Medicine have developed a pre-clinical model of the leading cause of central vision loss in older individuals, called dry age-related macular degeneration (dry AMD), and used it to identify new treatment modalities and drug targets.